ARWR logo

Arrowhead Pharmaceuticals, Inc.

ARWR
Healthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17

Clinical Trials (71)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT03936361
Statins In Intracerbral Hemorrhage
Intracerebral Hemorrhage
P3
Recruiting1,456RCT, Single-blindStatins
NCT06880770
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
Severe Hypertriglyceridemia
P3
Recruiting288RCT, Double-blindPlozasiran, Placebo
NCT06822790
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
P3
Active710Open-labelPlozasiran Injection
NCT07473843
Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia
Homozygous Familial Hypercholesterolemia
P3
Recruiting10Open-labelZodasiran
NCT07037771
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
Homozygous Familial Hypercholesterolemia
P3
Active70RCT, Double-blindzodasiran Injection, Placebo
NCT06700538
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Obesity
P1P2
Active190RCT, Double-blindARO-INHBE, Placebo, Tirzepatide
NCT06937203
A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Obesity, Diabetes Mellitus, Type 2
P1P2
Recruiting150RCT, Double-blindARO-ALK7, Placebo
NCT07241546
Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma
Asthma
P2
Recruiting36RCT, Double-blindARO-RAGE, Placebo
NCT07221344
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Alzheimer Disease, Alzheimer Disease, Early Onset
P1P2
Recruiting112RCT, Double-blindARO-MAPT-SC, Placebo
NCT07223658
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
Hyperlipidemia; Mixed
P1P2
Recruiting78RCT, Double-blindARO-DIMERPA, Placebo
NCT06543290
Azithromycin Before Induction
Infections
P1
Recruiting400RCT, Double-blindAzithromycin Pill, Placebo
NCT07662096
A First-In-Human Study of ARO-033 in Adult Participants
Age-related Macular Degeneration
P1
Recruiting84RCT, Double-blindARO-033, Placebo
NCT06672445
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
Spinocerebellar Ataxia Type 2
P1
Active39RCT, Double-blindARO-ATXN2 Injection, Placebo
NCT05400382
Maternal Mindfulness: Depression and Postpartum Pain
Depression, Unipolar, Pain, Postoperative
N/A
Recruiting75RCT, Open-label—
NCT06827288
Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
Opioid Use Disorder
N/A
Recruiting500RCT, Open-label—
NCT02299414
Chronic Hypertension and Pregnancy (CHAP) Project
Hypertension
P4
Completed2,408RCT, Open-labelAnti-hypertensive therapy
NCT01736449
Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Pterygium
P4
Completed31RCT, Open-labelBevacizumab
NCT06347003
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P3
Completed446RCT, Double-blindPlozasiran Injection, Placebo
NCT06366698
Intravenous Iron Versus Oral Iron for the Treatment of Iron Deficiency Anemia
Iron Deficiency Anemia of Pregnancy
P3
Unknown900RCT, Open-labelVenofer 200 MG Per 10 ML Injection, Ferrous sulfate
NCT05902598
A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome
P3
Completed37RCT, Double-blindPlozasiran, Placebon
NCT06347133
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Hypertriglyceridemia
P3
Completed1,456RCT, Double-blindPlozasiran Injection, Placebo
NCT03469947
California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA
Hemorrhagic Shock, Trauma Injury
P3
Completed200Open-labelTranexamic Acid
NCT06347016
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P3
Completed311RCT, Double-blindPlozasiran Injection, Placebo
NCT07056062
Oral Calcium Supplementation in Labor
Uterine Contraction, Labor Complication
P2P3
Completed89RCT, Open-labelCalcium carbonate
NCT05089084
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
Familial Chylomicronemia
P3
Completed75RCT, Double-blindPlozasiran, Placebo
NCT02604212
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
Hepatitis B
P2
Terminated32RCT, Double-blindARC-520, entecavir, antihistamine, tenofovir
NCT02738008
Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection
Hepatitis B
P2
Terminated12Open-labelARC-520 Injection, entecavir, tenofovir, antihistamine
NCT02349126
Study of ARC-520 in Patient With Chronic Hepatitis B Virus
Chronic Hepatitis B
P2
Withdrawn—Open-labelARC-520 Injection
NCT04720534
Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia
Severe Hypertriglyceridemia
P2
Completed229RCT, Double-blindARO-APOC3, Placebo
NCT05217667
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
Homozygous Familial Hypercholesterolemia
P2
Terminated18RCT, Open-labelARO-ANG 3 Injection
NCT02604199
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B
P2
Terminated58RCT, Double-blindARC-520 Injection, entecavir, tenofovir, antihistamine
NCT04375514
Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis
Cystic Fibrosis, Pulmonary
P1P2
Terminated43RCT, Double-blindARO-ENaC, Placebo
NCT02452528
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Chronic Hepatitis B
P2
Terminated4RCT, Double-blindARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
NCT03945292
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Alpha 1-Antitrypsin Deficiency
P2
Completed40RCT, Double-blindFazisiran Injection
NCT07859813
A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis
Metabolic Dysfunction-Associated Steatohepatitis
P2
Not Yet Recruiting252RCT, Double-blindARO-INHBE, Placebo
NCT02065336
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Hepatitis B, Chronic
P2
Terminated58RCT, Double-blindARC-520, Placebo, entecavir, chlorpheniramine
NCT04202354
Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH
Non-alcoholic Steatohepatitis
P1P2
Completed50RCT, Double-blindARO-HSD Injection, sterile normal saline (0.9% NaCl)
NCT02577029
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Hepatitis B, Hepatitis D
P2
Terminated79Open-labelARC-520, entecavir, pegylated interferon alpha 2a, tenofovir disoproxil, antihistamine
NCT05292950
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Asthma, Chronic Obstructive Pulmonary Disease
P1P2
Terminated78RCT, Double-blindARO-MUC5AC, Placebo
NCT03946449
Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)
Alpha 1-Antitrypsin Deficiency
P2
Completed16Open-labelARO-AAT
NCT03365947
Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)
Hepatitis B
P1P2
Completed114RCT, Double-blindARO-HBV, JNJ-56136379
NCT05083364
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
C3 Glomerulopathy, IgA Nephropathy
P1P2
Completed62RCT, Double-blindARO-C3, Placebo
NCT05537025
Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
P1P2
Completed105RCT, Double-blindARO-MMP7 Inhalation Solution, Placebo
NCT05276570
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease
Asthma
P1P2
Completed127RCT, Double-blindARO-RAGE, Placebo
NCT05413135
Study of ARO-APOC3 in Adults With Dyslipidemia
Dyslipidemias
P2
Completed418Open-labelARO-APOC3
NCT02900183
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
Alpha-1 Antitrypsin Deficiency
P2
Withdrawn—Open-labelARC-AAT Injection
NCT04998201
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
P2
Completed353RCT, Double-blindARO-APOC3, Placebo
NCT04832971
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
Mixed Dyslipidemia
P2
Completed204RCT, Double-blindARO-ANG3, Placebo
NCT03747224
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients
Dyslipidemias, Familial Hypercholesterolemia
P1
Completed93RCT, Double-blindARO-ANG3, sterile normal saline (0.9% NaCl)
NCT03362242
Study of ARO-AAT in Normal Adult Volunteers
Alpha 1-Antitrypsin Deficiency
P1
Completed45RCT, Double-blindARO-AAT Injection
NCT06209177
Study of ARO-CFB in Adult Healthy Volunteers
IgA Nephropathy
P1
Completed49RCT, Double-blindARO-CFB, Placebo
NCT05757596
Study of VSA001 Injection in Chinese Healthy Adult Volunteers
Healthy Adult Volunteers
P1
Completed24RCT, Double-blindVSA001 injection, Placebo
NCT02363946
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 Antitrypsin Deficiency
P1
Terminated65RCT, Double-blindARC-AAT Injection, Diphenhydramine
NCT04169711
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
P1
Completed26Open-labelARO-HIF2
NCT02535416
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Healthy
P1
Completed40Open-labelARC-520, cetirizine, diphenhydramine
NCT05533294
Study of ARO-RAGE in Healthy Subjects
Asthma
P1
Completed43RCT, Double-blindARO-RAGE Injection, Placebo
NCT03783377
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
Hypertriglyceridemia, Familial Chylomicronemia
P1
Completed112RCT, Double-blindARO-APOC3, sterile normal saline (0.9% NaCl)
NCT05949294
Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
P1
Withdrawn—Open-labelARO-SOD1 Injection
NCT02797522
A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
Hepatitis B
P1
Terminated47RCT, Double-blindARC-521 Injection, antihistamine, acetaminophen, entecavir, tenofovir
NCT01872065
Safety and Tolerability Study of ARC-520 in Healthy Volunteers
Healthy
P1
Completed54RCT, Double-blindARC-520, Placebo
NCT01465516
Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir
Hepatitis C Infection
Terminated105—Boceprevir
NCT06796426
Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS
Familial Chylomicronemia, High Risk Severe Hypertriglyceridemia (SHTG)
AVAILABLE——Plozasiran
NCT06402669
Extremity Trauma At a Level 1 Trauma Center
Trauma Injury, Trauma Blunt
Completed20,000——
NCT05897528
Insulin Regulation and Severity of Severe Acute Respiratory Syndrome COVID-19 Infection
COVID-19, Diabetes Mellitus
Completed589——
NCT05611398
Lactate Monitoring in Traumatic Long Bone Fractures Requiring Emergent Surgical Intervention
Lactate Blood Increase, Trauma Blunt
Completed164——
NCT05859958
ABO Blood Group Type Association With COVID-19 Severity
COVID-19, Blood Group Antigen Abnormality
Completed599——
NCT05888363
Management and Removal of Foreign Bodies in the Emergency Department
Rectal Foreign Body, Rectal Perforation
Completed78——
NCT05612867
Low Dose Vitamin C in Burns >20% Compared to Previous Studies With High Dose Vitamin C
Burns, Ascorbic Acid Deficiency
Completed54——
NCT05611385
Amphetamine Induced Adult Respiratory Distress Syndrome
Burns, Acute Lung Injury
Completed49——
NCT02485262
Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience
Hepatitis C
Unknown340—Sofosbuvir and simeprevir
NCT05964088
Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
Acute Kidney Injury
Completed267——